Cargando…
Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive...
Autores principales: | Parashar, Nidarshana Chaturvedi, Poddar, Jit, Chakrabarti, Sasanka, Parashar, Gaurav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417262/ https://www.ncbi.nlm.nih.gov/pubmed/32791240 http://dx.doi.org/10.1016/j.meegid.2020.104497 |
Ejemplares similares
-
Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2
por: Guo, Wenhan, et al.
Publicado: (2021) -
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021) -
A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein
por: Chen, Zhiqiang, et al.
Publicado: (2020) -
Aptamer/antibody sandwich method for digital detection of SARS-CoV2 nucleocapsid protein
por: Ge, Chenchen, et al.
Publicado: (2022) -
Repurposing CRISPR/Cas to Discover SARS‐CoV‐2 Detecting and Neutralizing Aptamers
por: Zhang, Ju, et al.
Publicado: (2023)